Showing 1 - 10 of 7,190
I investigate the contribution of pharmaceutical innovation to recent longevity growth in Germany and France. First, I examine the effect of the vintage of prescription drugs (and other variables) on the life expectancy and age-adjusted mortality rates of residents of Germany, using...
Persistent link: https://www.econbiz.de/10013069689
In this paper, we address the issue of spurious correlation in the production of health in a systematic way. Spurious correlation entails the risk of linking health status to medical (and nonmedical) inputs when no links exist. This note first presents the bounds testing procedure as a method to...
Persistent link: https://www.econbiz.de/10010315553
We use longitudinal, disease-level data to analyze the impact of pharmaceutical innovation on longevity and medical expenditure in Sweden, where mean age at death increased by 1.88 years during the period 1997-2010. Pharmaceutical innovation is estimated to have increased mean age at death by...
Persistent link: https://www.econbiz.de/10010283600
In this paper, we address the issue of spurious correlation in the production of health in a systematic way. Spurious correlation entails the risk of linking health status to medical (and nonmedical) inputs when no links exist. This note first presents the bounds testing procedure as a method to...
Persistent link: https://www.econbiz.de/10010285825
In this paper, we address the issue of spurious correlation in the production of health in a systematic way. Spurious correlation entails the risk of linking health status to medical (and nonmedical) inputs when no links exist. This note first presents the bounds testing procedure as a method to...
Persistent link: https://www.econbiz.de/10003900852
In this paper, we address the issue of spurious correlation in the production of health in a systematic way. Spurious correlation entails the risk of linking health status to medical (and nonmedical) inputs when no links exist. This note first presents the bounds testing procedure as a method to...
Persistent link: https://www.econbiz.de/10003909500
We use longitudinal, disease-level data to analyze the impact of pharmaceutical innovation on longevity and medical expenditure in Sweden, where mean age at death increased by 1.88 years during the period 1997-2010. Pharmaceutical innovation is estimated to have increased mean age at death by...
Persistent link: https://www.econbiz.de/10009571756
Innovations in cancer treatment have lowered mortality, but little is known about their economic benefits. We assess the effect of two decades of improvements in cancer treatment options on the labor market outcomes of breast and prostate cancer patients. In addition, we compare this effect...
Persistent link: https://www.econbiz.de/10012022431
Die Rolle der Hochschulen im Innovationssystem sowohl der BRD als auch der DDR hat sich in den letzten fünfzig Jahren zum Teil dramatisch geändert. Der Veränderungsprozess in der Bundesrepublik lässt sich grob in drei Phasen einteilen, die sich zwar überlappen, dennoch im wesentlichen eine...
Persistent link: https://www.econbiz.de/10010305667
Die Rolle der Hochschulen im Innovationssystem sowohl der BRD als auch der DDR hat sich in den letzten fünfzig Jahren zum Teil dramatisch geändert. Der Veränderungsprozess in der Bundesrepublik lässt sich grob in drei Phasen einteilen, die sich zwar überlappen, dennoch im wesentlichen eine...
Persistent link: https://www.econbiz.de/10010513698